CLAWSON JOHN G 4
4 · ENDOCYTE INC · Filed Feb 11, 2011
Insider Transaction Report
Form 4
ENDOCYTE INCECYT
CLAWSON JOHN G
Director
Transactions
- Conversion
Series C-3 Convertible Preferred Stock
2011-02-09−12,318→ 0 total→ Common Stock (12,318 underlying) - Conversion
Common Stock
2011-02-09+14,721→ 14,721 total - Conversion
Series A-1 Convertible Preferred Stock
2011-02-09−2,403→ 0 total→ Common Stock (2,403 underlying) - Award
Stock Option (right to buy)
2011-02-09+15,706→ 15,706 totalExercise: $7.23Exp: 2021-02-09→ Common Stock (15,706 underlying)
Footnotes (2)
- [F1]Each share of the Issuer's Series A-1, Series A-2, Series B, Series C-1, Series C-2 and Series C-3 Preferred Stock automatically converted into shares of Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.
- [F2]Shares subject to the option vest 1/3 of the shares upon the business day before each of the Issuer's first three annual stockholder meetings following February 9, 2011.